Amide Proton Transfer-weighted MRI combined with serum prostate-specific antigen levels for differentiating malignant prostate lesions from benign prostate lesions: a retrospective cohort study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1470-7330
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Amide Proton Transfer-weighted MRI combined with serum prostate-specific antigen levels for differentiating malignant prostate lesions from benign prostate lesions: a retrospective cohort study ; volume:23 ; number:1 ; day:7 ; month:1 ; year:2023 ; pages:1-8 ; date:12.2023
Cancer imaging ; 23, Heft 1 (7.1.2023), 1-8, 12.2023

Creator
Yang, Lu
Wang, Lei
Tan, Yuchuan
Dan, Hanli
Xian, Peng
Zhang, Yipeng
Tan, Yong
Lin, Meng
Zhang, Jiuquan
Contributor
SpringerLink (Online service)

DOI
10.1186/s40644-022-00515-w
URN
urn:nbn:de:101:1-2023031621403735613413
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Yang, Lu
  • Wang, Lei
  • Tan, Yuchuan
  • Dan, Hanli
  • Xian, Peng
  • Zhang, Yipeng
  • Tan, Yong
  • Lin, Meng
  • Zhang, Jiuquan
  • SpringerLink (Online service)

Other Objects (12)

Melanocytic lesions of the prostate

Melanocytic lesions of the prostate

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

T2 mapping for the characterization of prostate lesions

T2 mapping for the characterization of prostate lesions

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Related objects